Discontinued — last reported Q3 '22
Marvell Technology, Inc. Acquisitions remained flat by 0.0% to $2.60M in Q1 2025 compared to the prior quarter. Year-over-year, this metric grew by 147.3%, from -$5.50M to $2.60M. Over 3 years (FY 2022 to FY 2025), Acquisitions shows a downward trend with a -91.3% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.60B | $0.00 | -$60.44M | $15.21M | $44.00M | $54.60M | $4.40M | $9.30M | $0.00 | $5.50M | $0.00 | -$5.50M | $2.60M | $2.60M | $2.60M | $2.60M |
| QoQ Change | — | -100.0% | — | +125.2% | +189.3% | +24.1% | -91.9% | +111.4% | -100.0% | — | -100.0% | — | +147.3% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -98.8% | — | +107.3% | -38.8% | -100.0% | -89.9% | -100.0% | -159.1% | — | -52.7% | — | +147.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.